首页> 外文期刊>Genetics & Epigenetics >E-Cadherin, NFATC3, and PLP2 Are Differentially Methylated in Multiple Cancers
【24h】

E-Cadherin, NFATC3, and PLP2 Are Differentially Methylated in Multiple Cancers

机译:e-cadherin,nfatc3和PLP2在多种癌症中差异甲基化

获取原文
       

摘要

It is well documented that cancer cells have abnormal methylation patterns often caused by faulty methylating machinery. Specifically, E-cadherin, NFATC3 , and PLP2 are 3 genes known to be aberrantly methylated in cancer cells. These genes are well documented for their role in signaling pathways involved with cell proliferation, adhesion, migration, and other signs of tumor progression. Therefore, changes in gene expression of CDH1, NFATC3 , and PLP2 due to aberrant methylation can lead to profound changes in cellular function and tumor formation. In order to ensure that previous in vitro and in vivo methylation studies match what is observed in the clinic, we utilized a bioinformatics approach to complete an extensive analysis of methylation patterns of these 3 genes, analyzing over 5000 patient samples, across all cancers for which both normal and tumor tissues were available. Specifically, we analyzed overall and site-specific methylation patterns, at CpG islands and shores, of all 3 genes across 14 cancer types. Furthermore, we compared these methylation levels in normal and tumor samples of both matched and unmatched patient samples in order to determine any differences between groups. Finally, we examined whether an aberrant DNA methyltransferase, DNMT3B7 , known to be expressed in cancer cells and to alter methylation patterns in vitro correlated with altered overall and site-specific methylation of CDH1, NFATC3 , and PLP2 in these patient samples. Our results indicate that methylation patterns of CDH1 and NFATC3 were unexpectedly varied across tumors, contrary to previous studies performed in vitro , while PLP2 showed the expected hypomethylation pattern in tumor tissues. We also observed some correlation between DNMT3B7 expression and methylation patterns of these genes, but patterns were inconsistent. Taken together, these results emphasize the necessity for in vivo and patient studies rather than a complete reliance on in vitro data and provide multiple areas of future research.
机译:记录癌细胞经常由甲基化机械故障引起的甲基化模式异常。具体而言, e-cadherin,Nfatc3和 PLP2是已知在癌细胞中异常甲基化的3个基因。这些基因有很好的记录,用于其在涉及细胞增殖,粘附,迁移和肿瘤进展的其他迹象的信号传导途径中的作用。因此,由于异常甲基化引起的 CDH1,NFATC3和 PLP2的基因表达的变化可以导致细胞功能和肿瘤形成的深刻变化。为了确保在体内甲基化研究中先前的在体外和中匹配临床中观察到的内容,我们利用生物信息学方法来完成这3个基因的甲基化模式的广泛分析,分析了5000多个患者样品,在所有癌症上都可以使用正常和肿瘤组织的所有癌症。具体而言,我们在14种癌症类型中分析了所有3个基因的总体和位点特异性甲基化模式。此外,我们将这些甲基化水平与匹配和无与伦比的患者样品的正常和肿瘤样本进行了比较,以确定组之间的任何差异。最后,我们检查了是否在癌细胞中表达的异常DNA甲基转移酶, DNMT3B7,并在体外与甲基化图案改变甲基化图案,与 CDH1,NFATC3,NFATC3和CDH1,NFATC3的改变和位点特异性甲基化相关 PLP2在这些患者样品中。我们的结果表明,在肿瘤中出乎意料地改变了甲基化模式,与前一个研究相反,在体外进行,而 PLP2在肿瘤组织中显示了预期的低甲基化模式。我们还观察到这些基因的甲基化模式与这些基因的甲基化模式之间的一些相关性,但图案是不一致的。总之,这些结果强调了在体内和患者研究中的必要性,而不是完全依赖于对体外数据,并提供未来研究的多个领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号